Intervention Protocol

You have free access to this content

Memantine for schizophrenia

  1. Kamalpreet Kour1,
  2. Rupinder Kaur2,
  3. Jasvinder Singh3,*

Editorial Group: Cochrane Schizophrenia Group

Published Online: 6 JUN 2013

DOI: 10.1002/14651858.CD010552

How to Cite

Kour K, Kaur R, Singh J. Memantine for schizophrenia (Protocol). Cochrane Database of Systematic Reviews 2013, Issue 6. Art. No.: CD010552. DOI: 10.1002/14651858.CD010552.

Author Information

  1. 1

    Leeds Partnership Foundation Trust, Leeds, West Yorkshire, UK

  2. 2

    Meanwood, 22 Pennyfield Close, Leeds, UK

  3. 3

    Humber NHS Foundation Trust, Department of Psychological Medicine, Hull, UK

*Jasvinder Singh, Department of Psychological Medicine, Humber NHS Foundation Trust, 220-236 Anlaby Road, Hull, HU3 2RT, UK.

Publication History

  1. Publication Status: New
  2. Published Online: 6 JUN 2013



Additional references

Altman 1996
Awad 2008
Bland 1997
Boissel 1999
  • Boissel JP, Cucherat M, Li W, Chatellier G, Gueyffier F, Buyse M, et al. The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use [Apercu sur la problematique des indices d'efficacite therapeutique, 3: comparaison des indices et utilisation. Groupe d'etude des Indices d'efficacite]. Therapie 1999;54(4):405-11.
Bondi 2012
Carpenter 1994
Chen 2006
Deeks 2000
  • Deeks J. Issues in the selection for meta-analyses of binary data. Proceedings of the 8th International Cochrane Colloquium; 2000 Oct 25-28; Cape Town. Cape Town: The Cochrane Collaboration, 2000.
Divine 1992
Dominguez 2011
  • Dominguez E, Chin TY, Chen CP, Wu TY. Management of moderate to severe Alzheimer's disease: focus on memantine. Taiwanese Journal of Obstetrics & Gynecology 2011;50(4):415-23.
Donner 2002
Egger 1997
Elbourne 2002
  • Elbourne D, Altman DG, Higgins JPT, Curtina F, Worthingtond HV, Vaile A. Meta-analyses involving cross-over trials: Methodological issues. International Journal of Epidemiology 2002;31(1):140-9.
Furukawa 2006
  • Furukawa TA, Barbui C, Cipriani A, Brambilla P, Watanabe N. Imputing missing standard deviations in meta-analyses can provide accurate results. Journal of Clinical Epidemiology 2006;59(7):7-10.
Galderisi 2008
  • Galderisi S, Quarantelli M, Volpe U, Mucci A, Cassano GB, Invernizzi G, et al. Patterns of structural MRI abnormalities in deficit and nondeficit schizophrenia. Schizophrenia Bulletin 2008;34(2):393-401.
Gonda 2012
Gonzalez-Burgos 2012
  • Gonzalez-Burgos G, Lewis DA. NMDA receptor hypofunction, parvalbumin-positive neurons, and cortical gamma oscillations in schizophrenia. Schizophrenia Bulletin 2012;38(5):950-7.
Gulliford 1999
  • Gulliford MC. Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994. American Journal of Epidemiology 1999;149:876-83.
Higgins 2003
Higgins 2011
  • Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2011]. The Cochrane Collaboration, 2011. Available from
Hollmann 1994
Hutton 2009
Javitt 2010
Kay 1986
  • Kay SR, Opler LA, Fiszbein A. Positive and Negative Syndrome Scale (PANSS) Manual. North Tonawanda, NY: Multi-Health Systems, 1986.
Leucht 2005
Leucht 2005a
Leucht 2007
Lo 2011
Maekawa 2009
  • Maekawa M, Namba T, Suzuki E, Yuasa S, Kohsaka S, Uchino S. NMDA receptor antagonist memantine promotes cell proliferation and production of mature granule neurons in the adult hippocampus. Neuroscience Research 2009;63(4):259-66.
Marshall 2000
  • Marshall M, Lockwood A, Bradley C, Adams C, Joy C, Fenton M. Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia. British Journal of Psychiatry 2000;176:249-52.
Monaghan 2009
  • Monaghan DT, Jane DE. Pharmacology of NMDA Receptors. Biology of the NMDA Receptor 2009.
Mueser 2004
Olney 1995
Overall 1962
Picchioni 2007
Rund 2009
Schwartz 2012
Schünemann 2008
  • Schünemann HJ, Oxman AD, Vist GE, Higgins JPT, Deeks JJ, Glasziou P, et al. Chapter 12: Interpreting results and drawing conclusions. In: Higgins JPT, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions. The Cochrane Collaboration, 2008:359-83.
Sonkusare 2005
  • Sonkusare SK, Kaul CL, Ramarao P. Dementia of Alzheimer's disease and other neurodegenerative disorders--memantine, a new hope. Pharmacological Research : The Official Journal of the Italian Pharmacological Society 2005;51(1):1-17.
Stone 2007
  • Stone JM, Pilowsky LS. Novel targets for drugs in schizophrenia. CNS & Neurological Disorders Drug Targets 2007;6(4):265-72.
Ukoumunne 1999
  • Ukoumunne OC, Gulliford MC, Chinn S, Sterne JAC, Burney PGJ. Methods for evaluating area-wide and organistation-based intervention in health and health care: a systematic review. Health Technology Assessment 1999;3(5):1-75.
Xia 2009
  • Xia J, Adams CE, Bhagat N, Bhagat V, Bhoopathi P, El-Sayeh H, et al. Loss to outcomes stakeholder survey: the LOSS study. Psychiatric Bulletin 2009;33(7):254-7.